The absence of a BBB profile is not inherently negative, as many newer companies have not yet been evaluated, but combined with the below-average Trustpilot scores, it leaves patients with fewer avenues for recourse if issues arise
That changed in 2023 when Cost Plus partnered with Coherus BioSciences to offer YUSIMRY (adalimumab-aqvh), a biosimilar of Humira, for $569.27 far below Humiras list price of approximately $7,000 per month [10]
The system has limits (testing costs $50-100 per sample), but it's the closest thing to a quality guarantee outside the pharma supply chain
So, diet and exercise are regularly checked in placebo-controlled trials
This peptide also helps to improve energy levels, making it easier to maintain an active lifestyle